The histories of Ireland and the U.S. are woven together into one tightly knit fabric laced with the green of the Emerald ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Plus, the National Academy of Sciences received $20 million, Agnes Scott College got $15 million, and three other ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

More than 1,300 Florida A&M University students turned their tassels during the spring commencement at the Alfred Lawson Jr.

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...